According to Fortune Business Insights, the global allergy immunotherapy market size was valued at USD 1.99 billion in 2025 and is anticipated to grow from USD 2.17 billion in 2026 to USD 5.14 billion by 2034, exhibiting a CAGR of 11.38% during the forecast period. Europe dominated the allergy immunotherapy market with a market share of 71.08% in 2025.
Allergy immunotherapy is a treatment approach designed to reduce sensitivity to specific allergens by gradually exposing patients to controlled doses of allergenic substances. Unlike symptomatic treatments, immunotherapy targets the underlying cause of allergic reactions and offers long-term disease modification benefits. It is widely used for conditions such as allergic rhinitis, allergic asthma, and other allergy-related disorders.
Key Market Drivers
Rising Prevalence of Allergic Disorders
The growing incidence of allergic rhinitis, allergic asthma, and environmental allergies is driving demand for effective long-term treatment solutions.
Increasing Awareness of Disease-Modifying Therapies
Patients and healthcare providers are increasingly adopting immunotherapy due to its ability to address the root cause of allergies rather than only managing symptoms.
Advancements in Allergy Treatment Technologies
Continuous innovation in allergen extracts, delivery methods, and treatment protocols is improving patient outcomes and treatment convenience.
Market Restraints
Long Treatment Duration
Allergy immunotherapy often requires extended treatment periods, which may affect patient adherence and treatment completion rates.
Risk of Adverse Reactions
Although generally safe, immunotherapy may cause allergic reactions in certain patients, requiring careful monitoring.
Get Sample PDF Here: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/allergy-immunotherapy-market-100727
Market Opportunities
Growing Adoption of Sublingual Immunotherapy
The increasing preference for non-invasive and patient-friendly treatment options is creating significant opportunities for market growth.
Expansion in Emerging Healthcare Markets
Improving healthcare access and growing awareness of allergy management in developing regions are expected to support future demand.
Segmentation
By Type
- Subcutaneous Immunotherapy
- Sublingual Immunotherapy
By Application
- Allergic Rhinitis
- Allergic Asthma
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Online Pharmacies
Regional Insights
Europe
Europe dominated the allergy immunotherapy market with a share of 71.08% in 2025. The region benefits from high awareness of allergy treatments, strong adoption of immunotherapy, favorable reimbursement frameworks, and the presence of leading manufacturers specializing in allergy therapeutics.
North America
North America is witnessing significant growth due to the increasing prevalence of allergic conditions, growing healthcare expenditure, and expanding adoption of advanced allergy treatments.
Asia Pacific
Asia Pacific is expected to experience rapid growth during the forecast period due to rising allergy incidence, improving healthcare infrastructure, and increasing awareness regarding long-term allergy management.
Rest of the World
Latin America and the Middle East & Africa are gradually adopting allergy immunotherapy solutions as healthcare systems expand and patient awareness continues to improve.
Get Sample PDF Here: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/allergy-immunotherapy-market-100727
Key Players in the Allergy Immunotherapy Market
- ALK-Abelló A/S
- Stallergenes Greer
- HAL Allergy Group
- Allergy Therapeutics plc
- LETI Pharma S.L.U.
- Jubilant HollisterStier LLC
- Torii Pharmaceutical Co., Ltd.
- Merck KGaA
- Anergis SA
- Circassia Group plc
Conclusion
The global allergy immunotherapy market is expected to witness strong growth through 2034, driven by the increasing prevalence of allergic diseases, rising awareness of disease-modifying therapies, and advancements in immunotherapy technologies. The growing adoption of sublingual immunotherapy, expanding healthcare access, and increasing focus on long-term allergy management are expected to create significant growth opportunities for market participants during the forecast period.